ECCEO 9-IOF | ATHENS | GREECE | March 18 - 21, 2009 | Megaron Athens International Conference Centre

Thursday - MARCH 19

09.00 - 11.50 SCIENTIFIC SESSION I
Chairs: Socrates Papapoulos & Georges Lyritis
09.00 - 09.30 Plenary lecture 1
Implications of improving adherence to osteoporosis treatment
Speaker: Stuart Silverman
09.30 - 09.50 Remittance of the ESCEO-Amgen fellowships + Remittance of the Amgen - IOF Grants
09.50 - 10.20 Oral communications selected from abstracts
10.20 - 10.50 Plenary lecture 2

 

Secular trends in osteoporosis fracture: myth or reality
  Speaker: Cyrus Cooper
10.50 - 11.50 Oral communications selected from abstracts
12.15 - 13.45 Lunch Symposium Lunch Symposium
Forming bone for superior antifracture efficacy New approaches to prevent osteoporotic fractures and invasive breast cancer in postmenopausal women
Sponsored by SERVIER
AUDITORIUM 1 - TRIANTI HALL
Sponsored by ELI LILLY
AUDITORIUM 2 - SKALKOTAS HALL
Chairs: G. LYRITIS & J.-Y. REGINSTER Chairs: G. TROVAS & D. AGNUSDEI
Introduction G. LYRITIS Postmenopausal osteoporosis: effects of treatments on bone quality parameters A. DIEZ
Osteoblast, a key player in osteoporosis J.P.T.M. VAN LEEUWEN Clinical use of teriparatide in patients with severe osteoporosis O. LUNDGREN
Protelos: better efficacy on bone microarchitecture... J.E. CABRAL DA FONSECA Role of SERMs in the prevention of fragility fractures and invasive breast cancer in postmenopausal women P. HADJI
... for superior efficacy against fracture R. RIZZOLI  
How does the efficacy of Protelos translate into patient benefits J.-Y. REGINSTER  
Conclusion J.-Y. REGINSTER  
13.45 - 15.00 Poster Session & Exhibition Viewing
14.00 - 15.00 EDUCATIONAL LECTURE MEET-THE-PROFESSOR SESSIONS - Amgen
  How to present scientific data in a first-line meeting: strengths and weaknesses - Socrates Papapoulos Use and misuse of bone densitometry in the diagnosis and follow up of osteoporotic patients - Jean-Pierre Devogelaer
    Role of rehabilitation medicine in the management of osteoporosis and osteoarthritis - Olivier Bruyère
    Management of corticoid-induced osteoporosis - Cyrus Cooper
    Muscles and bones - Dieter Felsenberg
    Use and misuse of MRI in the diagnosis and management of ostheoarthritis - Jean-Pierre Pelletier
   
15.00 - 16.45 SCIENTIFIC SESSION II
  Chairs: Cyrus Cooper & Steve Cummings
15.00 - 15.30 Plenary lecture 3
  Imaging of bone microarchitecture and osteoporosis
Speaker: Sharmila Majumdar
15.30 - 16.30 Oral communications selected from abstracts
17.00 - 18.30 Symposium Symposium
Zoledronic acid – Optimizing our control of osteoporosis New role of chondroitin sulfate in the management of OA
Sponsored by NOVARTIS PHARMA AG
AUDITORIUM 1 - TRIANTI HALL
Sponsored by IBSA GENEVRIER
AUDITORIUM 2 - SKALKOTAS HALL
Chair: S.E. PAPAPOULOS Chair: J.-Y. REGINSTER
Welcome and introduction S.E. PAPAPOULOS Welcome and introduction Not all chondroitin sulfates are the same N. VOLPI
Optimizing real-world outcomes in osteoporosis care S.E. PAPAPOULOS Symptomatic and structure modifying activities of chondroitin sulfate: the first complete meta-analysis base on raw data D. UEBELHART
Advancing standards in osteoporosis S. BOONEN New data for the management of osteoarthritis O. BRUYERE
Achieving rapid and sustained efficacy in osteoporosis care E.F. ERIKSEN Guidelines for osteoarthritis and structure modification E. MAHEU
Providing effective therapy across a broad spectrum of osteoporosis patients P. SAMBROOK Discussion and conclusion
Closing remarks S.E. PAPAPOULOS